

	Immunomodulatory Agents	Antiviral Agents	Antimicrobial Agents
<b>Severe/Critically Ill Patients</b>			
Patients requiring high-flow oxygen or admitted to the critical care unit requiring invasive mechanical ventilation	<ul style="list-style-type: none"> <li><input checked="" type="checkbox"/> <b>Tocilizumab (or Sarilumab)</b> 400 mg IV x 1 dose <b>OR</b></li> <li><b>Baricitinib</b> 4 mg PO/NG daily x 14 days (or until discharge) See criteria for <a href="#">Critically Ill Patients</a></li> <li><input checked="" type="checkbox"/> <b>Dexamethasone</b> 6 mg PO/IV daily x 10 days (or at discharge if sooner). If IL-6 inhibitors and Baricitinib are unavailable, a dose of <b>12 mg</b> can be used (<i>based on low certainty evidence</i>)</li> </ul>	<ul style="list-style-type: none"> <li><input checked="" type="checkbox"/> <b>Remdesivir</b> Not recommended</li> </ul>	<ul style="list-style-type: none"> <li><input checked="" type="checkbox"/> <b>Empiric Antibiotics</b> Bacterial co-infection is <b>uncommon</b> in COVID-19. Antimicrobial therapy is <b>not indicated</b> unless concomitant bacterial infection is strongly suspected.</li> </ul>
<b>Moderate to Severely Ill Patients</b>			
Patients requiring low-flow oxygen <b>at least 40% FiO<sub>2</sub></b> who are managed on the medicine ward	<ul style="list-style-type: none"> <li><input type="checkbox"/> <b>Tocilizumab (or Sarilumab)</b> 400 mg IV x 1 dose <b>OR</b></li> <li><b>Baricitinib</b> 4 mg PO/NG daily x 14 days (or until discharge) See criteria for <a href="#">Moderate to Severely Ill Patients</a></li> <li><input checked="" type="checkbox"/> <b>Dexamethasone</b> 6 mg PO/IV daily x 10 days (or at discharge if sooner)</li> </ul>	<ul style="list-style-type: none"> <li><input checked="" type="checkbox"/> <b>Remdesivir</b> Not recommended</li> </ul>	<ul style="list-style-type: none"> <li><input checked="" type="checkbox"/> <b>Empiric Antibiotics</b> Bacterial co-infection is <b>uncommon</b> in COVID-19. Antimicrobial therapy is <b>not indicated</b> in this setting.  <a href="#">See ASP guidance on antimicrobial use in COVID-19.</a></li> </ul>
<b>Moderately Ill Patients</b>			
Patients requiring low-flow oxygen <b>less than 40% FiO<sub>2</sub></b> who are managed on the medical ward	<ul style="list-style-type: none"> <li><input checked="" type="checkbox"/> <b>Dexamethasone</b> 6 mg PO/IV daily x 10 days (or at discharge if sooner)</li> </ul>	<ul style="list-style-type: none"> <li><input checked="" type="checkbox"/> <b>Remdesivir</b> 200 mg IV x 1 dose, then 100 mg IV daily x 4 days. See criteria for <a href="#">Moderately Ill Patients</a></li> </ul>	<ul style="list-style-type: none"> <li><input checked="" type="checkbox"/> <b>Empiric Antibiotics</b> Bacterial co-infection is <b>uncommon</b> in COVID-19. Antimicrobial therapy is <b>not indicated</b> in this setting.  <a href="#">See ASP guidance on antimicrobial use in COVID-19.</a></li> </ul>
<b>Mildly Ill Patients - Patients who are not on any new or additional supportive oxygen</b>			
<p>See <a href="#">Science Table Guidelines</a> for criteria or try the <a href="#">Osler COVID Treatment Tool</a></p> <p>For Remdesivir eligibility, please refer to Osler's criteria for <a href="#">Mildly Ill Patients</a></p>	Ambulatory Patients		<ul style="list-style-type: none"> <li><input checked="" type="checkbox"/> <b>Empiric Antibiotics</b> Bacterial co-infection is <b>uncommon</b> in COVID-19. Antimicrobial therapy is <b>not indicated</b> in this setting. <a href="#">See ASP guidance on antimicrobial use in COVID-19.</a></li> </ul>
	<ul style="list-style-type: none"> <li><input checked="" type="checkbox"/> <b>Nirmatrelvir/Ritonavir (Paxlovid®)</b> PO twice daily x 5 days <i>Available at depot locations or outpatient pharmacies</i></li> </ul>		
	Admitted Patients ( <i>including patients admitted in ER</i> )		
		<ul style="list-style-type: none"> <li><input checked="" type="checkbox"/> <b>Remdesivir</b> 200 mg IV x 1 dose, then 100 mg IV daily x 2 days. See criteria for <a href="#">Mildly Ill Patients</a></li> </ul>	